Release date- 30082019 - WALTHAM - Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin
therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present a corporate overview at the Wells Fargo Securities2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05pm ET, in Boston.
Through their partnership, Morphic and Schrodinger have accelerated the discovery and design of potent and selective integrin
inhibitors and activators targeting serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
(15) It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin
, inhibiting the binding of alpha4beta7 integrin
to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).
Protagonist Therapeutics announced results from the initial single ascending dose part of the Phase 1 study of PN-943, an oral, gut-restricted alpha-4-beta-7 integrin
specific antagonist in development for the potential treatment of inflammatory bowel disease.
Morphic Therapeutic, a biotechnology company developing oral integrin
therapies, has signed a research and development collaboration with United States-based Janssen Biotech, it was reported on Friday.
The researchers found that specialised white blood cells called regulatory T cells from Crohn's patients produced less of a gut-specific protein called integrin
EAA4EAA7 than regulatory T cells from healthy people.
Global Banking News-October 19, 2018-AbbVie & Morphic partnership to develop oral integrin
drugs targeting fibrotic diseases
(EA Pharma) have revealed a mechanism in which an analogue (ER-464195-01) of Eisai's in-house discovered E6007 inhibits integrin
activation by dissociating interaction between calreticulin (CRT) and integrin
alpha 4 (ITGA4), suppressing adhesion and infiltration of leukocytes overall.
Later, at the Trochophore stage (24 hpf), [beta]1-like integrin
was detectable in the developing stomach area.
(3) Moreover, some studies showed that the adhesion capacity of highly metastatic cells could be reduced by inhibiting integrin
expression or modifies the process that leads metastatic cells to anoikis, which is programmed cell death that is induced upon cell detachment from ECM.